Auger Electron Therapy Enhanced by Heat-Triggered Release of I-125-Labeled DNA-Targeted Compounds within the Tumor Microenvironment

IF 4.9 2区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Molecular Pharmaceutics Pub Date : 2026-09-07 Epub Date: 2026-07-24 DOI:10.1021/acs.molpharmaceut.6c00443
Masayuki Munekane, Kazuki Matsunaga, Miki Ozaki, Hiroaki Echigo, Kenji Mishiro, Takeshi Fuchigami, Kazuma Ogawa
{"title":"Auger Electron Therapy Enhanced by Heat-Triggered Release of I-125-Labeled DNA-Targeted Compounds within the Tumor Microenvironment","authors":"Masayuki Munekane,&nbsp;Kazuki Matsunaga,&nbsp;Miki Ozaki,&nbsp;Hiroaki Echigo,&nbsp;Kenji Mishiro,&nbsp;Takeshi Fuchigami,&nbsp;Kazuma Ogawa","doi":"10.1021/acs.molpharmaceut.6c00443","DOIUrl":null,"url":null,"abstract":"<p>In Auger electron therapy, the effective delivery of\r\nAuger electron-emitting\r\nradionuclides to the nuclei of cancer cells is essential for achieving\r\nhigh therapeutic efficacy. In this study, we developed a novel strategy\r\nthat combined thermosensitive liposomes (TSLs) encapsulating <sup>125</sup>I-labeled DNA-targeted compounds. This approach enabled\r\nenhanced tumor accumulation via TSL-mediated delivery and efficient\r\nnuclear translocation of radioactivity by releasing an <sup>125</sup>I-labeled doxorubicin derivative ([<sup>125</sup>I]I-DOX) within\r\nthe tumor microenvironment. [<sup>125</sup>I]I-DOX exhibited high\r\ncellular and nuclear uptake, producing potent cytotoxicity through\r\nAuger electrons emitted from <sup>125</sup>I. [<sup>125</sup>I]I-DOX-loaded\r\nTSLs efficiently released [<sup>125</sup>I]I-DOX at 43 °C, enhancing\r\nits cellular uptake by Colon-26 cells. Tumor accumulation of radioactivity\r\nin the heating group was much higher than in the nonheating group,\r\nand the accumulation was maintained for up to 48 h postinjection.\r\nIntravenous injection of [<sup>125</sup>I]I-DOX-loaded TSLs (5.0 MBq)\r\nand localized tumor heating significantly inhibited tumor growth without\r\nbody weight loss. The combination of [<sup>125</sup>I]I-DOX-loaded\r\nTSLs and hyperthermia represents a promising strategy for Auger electron\r\ntherapy targeting the nuclei of cancer cells.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 9","pages":"4681–4689"},"PeriodicalIF":4.9000,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Pharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.6c00443","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/24 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

In Auger electron therapy, the effective delivery of Auger electron-emitting radionuclides to the nuclei of cancer cells is essential for achieving high therapeutic efficacy. In this study, we developed a novel strategy that combined thermosensitive liposomes (TSLs) encapsulating 125I-labeled DNA-targeted compounds. This approach enabled enhanced tumor accumulation via TSL-mediated delivery and efficient nuclear translocation of radioactivity by releasing an 125I-labeled doxorubicin derivative ([125I]I-DOX) within the tumor microenvironment. [125I]I-DOX exhibited high cellular and nuclear uptake, producing potent cytotoxicity through Auger electrons emitted from 125I. [125I]I-DOX-loaded TSLs efficiently released [125I]I-DOX at 43 °C, enhancing its cellular uptake by Colon-26 cells. Tumor accumulation of radioactivity in the heating group was much higher than in the nonheating group, and the accumulation was maintained for up to 48 h postinjection. Intravenous injection of [125I]I-DOX-loaded TSLs (5.0 MBq) and localized tumor heating significantly inhibited tumor growth without body weight loss. The combination of [125I]I-DOX-loaded TSLs and hyperthermia represents a promising strategy for Auger electron therapy targeting the nuclei of cancer cells.

在肿瘤微环境中热触发释放i -125标记的dna靶向化合物增强了俄歇电子治疗。
在俄歇电子治疗中,将俄歇电子发射放射性核素有效地递送到癌细胞的细胞核中是获得高治疗效果的关键。在这项研究中,我们开发了一种新的策略,即用热敏脂质体(TSLs)包封125i标记的dna靶向化合物。该方法通过在肿瘤微环境中释放一种125I标记的阿霉素衍生物([125I]I-DOX),通过tsl介导的递送和放射性的有效核易位,增强了肿瘤的积累。[125I]I-DOX表现出高细胞和核摄取,通过125I发射的俄歇电子产生强大的细胞毒性。[125I]I-DOX负载的TSLs在43°C时有效释放[125I]I-DOX,增强了col -26细胞对其的摄取。加热组的肿瘤放射性积累远高于未加热组,并在注射后48 h内持续积累。静脉注射负载[125I] i - dox的TSLs (5.0 MBq)并局部加热肿瘤,可显著抑制肿瘤生长,且不减轻体重。[125I] i - dox负载TSLs和热疗的结合代表了针对癌细胞核的俄格电子治疗的一种有前途的策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Molecular Pharmaceutics
Molecular Pharmaceutics 医学-药学
CiteScore
8.00
自引率
6.10%
发文量
391
审稿时长
2 months
期刊介绍: Molecular Pharmaceutics publishes the results of original research that contributes significantly to the molecular mechanistic understanding of drug delivery and drug delivery systems. The journal encourages contributions describing research at the interface of drug discovery and drug development. Scientific areas within the scope of the journal include physical and pharmaceutical chemistry, biochemistry and biophysics, molecular and cellular biology, and polymer and materials science as they relate to drug and drug delivery system efficacy. Mechanistic Drug Delivery and Drug Targeting research on modulating activity and efficacy of a drug or drug product is within the scope of Molecular Pharmaceutics. Theoretical and experimental peer-reviewed research articles, communications, reviews, and perspectives are welcomed.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书